Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:54 pm EST
Share
Eyenovia, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.001198 million. Net loss was USD 7.34 million compared to USD 7.31 million a year ago.
For the nine months, sales was USD 0.001198 million. Net loss was USD 19.29 million compared to USD 21.89 million a year ago. Basic loss per share from continuing operations was USD 0.5.
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.